For instance, AR is starting to be recognized as attractive target in triple-negative (ER-/PR-/Her2-) breast cancer (55) and may be a critical target in other human malignancies in which sex differences exist in incidence and mortality, such as bladder cancer and hepatic cell carcinoma (56, 57). The gene discussed is ERBB2; the disease is breast carcinoma.